Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From Two Open-Label, Phase 1 Studies

Journal:

Clinical Infectious Diseases

Published:

2026-03-14

DOI:

10.1093/cid/ciag135

Affiliations:

7

Authors:

20

Go to article

Institutions	Authors	Share
Merck - Rahway, United States of America (USA)	11.000000 11.000000	0.55
MSD Belgium, Belgium	4.000000	0.20
National Institute of Infectious Diseases "Prof. Dr. Matei Bals" (INBIMB), Romania	1.500000	0.08
Desmond Tutu Health Foundation (DTHF), South Africa	1.000000	0.05
Helen Joseph Hospital, South Africa	1.000000	0.05
Josha Research, South Africa	1.000000	0.05
Carol Davila University of Medicine and Pharmacy (UMFCD), Romania	0.500000	0.03

Interested in Clinical Sciences?